---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-026761"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T13:50:57.023526+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics FY2025 net loss $9.6M; $135M placement extends cash into Q1 2029

## Summary
- Net loss of $9.6M improved from $126.6M in 2024; collaboration revenue from BMS rose to $109.2M (from $6.6M).
- Cash, cash equivalents, and securities $117.1M at Dec 31, 2025; with $135M Jan 2026 placement, runway extended to Q1 2029.
- CNTY-813 (T1D beta islet therapy) IND submission expected Q4 2026; initial clinical data anticipated 2H 2027.
- CNTY-308 (CD19-targeted CAR-iT) on track for clinical entry in 2026; CARAMEL IST data expected later this year.
- Strengthened balance sheet via oversubscribed $135M private placement led by TCGX; new board members appointed.

## SEC filing metadata
- accession: 0001104659-26-026761
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465926026761/0001104659-26-026761-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465926026761/tm268574d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-026761
- JSON: https://secwatch.observer/filing/0001104659-26-026761.json
- Plain text: https://secwatch.observer/filing/0001104659-26-026761.txt

## Key facts
- Earnings Releases
  Century Therapeutics, Inc. reported the full year ended December 31, 2025 results: revenue $109.2 million.
  - Period: the full year ended December 31, 2025
  - Revenue: $109.2 million
  - Result: reported results
  source text: first quarter of 2029. · Collaboration Revenue: Collaboration revenue generated through the company’s collaboration, option, and license agreement with Bristol-Myers Squibb was $109.2 million for the year ended December 31, 2025, compared to $6.6 million for the same period in 2024. · Research and Development (R&D) Expenses: R&D expenses were $95.7 million for the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850119/000110465926026761/0001104659-26-026761-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.